Researchers are working on an array of different COVID-19 vaccines
A Visual Guide to different approaches being taken by scientists to develop the vaccine
As the various countries of the World begin to emerge from weeks of lockdown, the focus is shifting developing a global vaccine for the pandemic which has infected more than 5.7 million and taken lives in excess of 357,000 at the time of writing. The World Health Organization (WHO) has already warned that the pandemic is by no means over as we see major outbreaks in countries like Brazil, Russia & India.
Governments in countries where they are re-opening their economies for the business need to tread very carefully between facing further financial hardship and causing more suffering from the pandemic. Last weekend, U.S-based biotech Novavax was all over the news with its NVX‑CoV2373 vaccine candidate.
The company announced that it has begun enrolling its first human participants in a Phase 1/2 clinical trial, whose immunogenicity and safety results are expected in July 2020. It is hinging its hopes on the proprietary nanoparticle technology and Matrix‑M adjuvant — used in its promising flu vaccine, NanoFlu, to create an effective COVID-19 vaccine.
